Tuesday, June 6, 2023
Home Tags TNTY

Tag: TNTY

Mitesco
Research

Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165%...

Editor / Curator -
Mitesco Inc,. Biotech Stock Review
All News

Biotech Stock Review: Mitesco (MITI) $0.03, Report Update

Editor / Curator -
Telehealth

True Nature | Mitesco (MITI) Raising $15 Million.

Editor / Curator -
Superbug News - CoronaVirus Watch List

Telehealth DTC Startup Ro is now Offering Coronavirus Assessments (ModernRetail).

Editor / Curator -
Biotech News

Our Favorite Incubator, Incubates! Telehealth in its Future?

Editor / Curator -
All News

Citius Pharma (CTXR), Fortress Biotech (FBIO) and True Nature (TNTY) Significantly...

Editor / Curator -
Biotech News

True Nature|Mitesco (TNTY). Coverage Report Issued.

Editor / Curator -
Biotech News

Mass General Brigham to Invest $100 Million in Telehealth and Digital...

Editor / Curator -
Mitesco, Biotech Stock Review
Incubator

True Nature (TNTY), a Medtech Startup Incubator Pays Down Some Toxic...

Editor / Curator -
True Nature, Mitesco, Biotech Stock Review
Incubator

Is True Nature (TNTY) $0.04, Nearing a Breakout?

Editor / Curator -
12Page 1 of 2

Latest article

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

2022 Watch List Editor / Curator -
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

2020 Watch List Editor / Curator -
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...

2023 Watch List Editor / Curator -
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.